Table 1

 Characteristics of 46 patients with spondylarthropathy with at least one uveitis flare, and treated with anti-tumour necrosis factor (TNF) antibody and soluble TNF receptor between December 1997 and December 2004

CharacteristicsAll patients(n = 46)Anti-TNF antibodiesinfliximab andadalimumab(n = 33)Soluble TNF receptor etanercept(n = 13)p Value*
*p Value of the comparison between the patients treated with antibody and those treated with soluble receptor.
†Positivity is given on known data.
SD, standard deviation; DMARD, disease-modifying anti-rheumatic drug; HLA, human leucocyte antigen; TNF: tumor necrosis factor.
Age at first symptoms, mean (SD), years25.9 (9.2)26.0 (9.6)25.9 (8.5)0.7
Age at initiation of anti-TNF treatment, mean (SD), years40.0 (10.3)41.1 (9.6)37.3 (11.8)0.3
Male, n (%)33 (71.7)24 (72.7)9 (69.2)1
Predominant clinical form of spondylarthropathy for which anti-TNF was prescribed1
    Axial, n (%)33 (71.8)23 (69.9)10 (76.9)
    Peripheral, n (%)9 (19.5)6 (18.1)3 (23.1)
    Enthesitic, n (%)1 (2.2)1 (3.0)0
    Undetermined, n (%)3 (6.5)3 (9.0)0
HLA B27: ± known: n (%)†36/40 (90.0)26/28 (92.9)10/12 (83.3)0.6
One concomitant DMARD: yes, n (%)15 (32.6)12 (36.4)3 (23.1)0.5
Concomitant corticosteroids: yes, n (%)12 (26.1)11 (33.3)1 (7.7)0.1